Search

Displaying results 4721 - 4730 of 10000 in total
  1. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis. … Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].

  2. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. … FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.

  3. Drug

    Tocopherylquinone

    go.drugbank.com/drugs/DB14094
    Investigational

    Synonyms: Vitamin E quinoneCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Morin

    go.drugbank.com/drugs/DB16770
    Experimental

    Synonyms: Al-MorinCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    3,4-Dihydroxybenzoic Acid

    go.drugbank.com/drugs/DB03946
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Zastaprazan

    go.drugbank.com/drugs/DB21524
    Investigational

    Zastaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation. … Zastaprazan has a monoisotopic molecular weight of 362.21 Da.

  7. Drug

    Linaprazan

    go.drugbank.com/drugs/DB20602
    Investigational

    Linaprazan is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation. … Linaprazan is under investigation in clinical trial NCT00206284 (A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.).

  8. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  9. Drug

    BI 44370 TA

    go.drugbank.com/drugs/DB16037
    Investigational

    BI 44370 TA is under investigation in clinical trial NCT00751803 (BI 44370 TA in Acute Migraine Attack).

  10. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.